Cassava Sciences INC Form 4 insider transactions

Director Robert Gussin acquired 15,000 stock options in Cassava Sciences Inc. on May 9, 2024, as part of the Non-employee Director Compensation Program.

Director Michael J. O'Donnell of Cassava Sciences Inc. reports the acquisition of stock options as part of the Non-employee Director Compensation Program.

Director Richard Barry reports receiving a stock option grant for 15,000 shares of Cassava Sciences (SAVA) on May 9, 2024.

Director Sanford Robertson acquired 15,000 stock options in Cassava Sciences Inc. on May 9, 2024, as part of the Non-employee Director Compensation Program.

Director Patrick J. Scannon received 10,000 stock options in Cassava Sciences Inc. on May 9, 2024, as part of the Non-employee Director Compensation Program.

Director Robert Eugene Anderson Jr. acquired 10,000 stock options in Cassava Sciences Inc. on May 9, 2024, according to a Form 4 filing.

Director Pierre Gravier acquired 10,000 stock options in Cassava Sciences Inc. on May 9, 2024, as part of the Non-employee Director Compensation Program.

Director Claude Nicaise of Cassava Sciences Inc. received 10,000 stock options on May 9, 2024, as part of the company's Non-employee Director Compensation Program.

Director Robertson Sanford exercised common stock warrants of Cassava Sciences Inc. on April 26, 2024, acquiring 69,000 shares.

Director Richard Barry exercises warrants to acquire 176,085 shares of Cassava Sciences common stock.

James William Kupiec, Chief Medical Officer of Cassava Sciences, exercised common stock warrants on April 18, 2024, acquiring 1,500 shares.

Eric Schoen, CFO of Cassava Sciences, reports exercising common stock warrants for cash, resulting in the acquisition of 1,500 shares.